# Tumour and Signalling WS 2021/2022

Seminar, Mondays, 17:00, venue to be announced

<table>
<thead>
<tr>
<th>Name</th>
<th>Topic</th>
<th>Date</th>
<th>Advisor</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weiß, Annika</td>
<td>Scientific highlights of the UGLy Retreat (21-23 September 2021) *</td>
<td>11.10.21</td>
<td>Klump</td>
<td></td>
</tr>
<tr>
<td>Shoibab, Rao</td>
<td>Extracellular vesicles as new informative biomarkers in pediatric acute myeloid leukemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saoub, Stefanie</td>
<td>The interaction between hypoxia-inducible factors and the tumour suppressor p53 in the inflammatory colorectal carcinoma</td>
<td>25.10.21</td>
<td>Göthert</td>
<td></td>
</tr>
<tr>
<td>Ullrich, Vivien</td>
<td>Targeting clonally expanding drug-resistant tumour cells in recurrent glioblastoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Zhen</td>
<td>The role and the underlying mechanism of ALDH1A3 in glioblastoma</td>
<td>22.11.21</td>
<td>Gellhaus</td>
<td></td>
</tr>
<tr>
<td>Kerkhoff, Maximilian</td>
<td>Establishment of a CAM model for predicting and evaluating the responsiveness of systemic therapies in Ewing and osteosarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmon, Carolin</td>
<td>Liquid biopsy investigations to clarify the tumour evolution of ovarian carcinoma and to develop personalised therapy concepts</td>
<td>6.12.21</td>
<td>Seifert</td>
<td></td>
</tr>
<tr>
<td>Emmerich, Sarah</td>
<td>Characterisation of the resistant mechanism to p300/CPB inhibition in NUT midline carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Meenen, Dario</td>
<td>Impact of an ADAM10 and ADAM 17 knockdown on the tumorigenicity of retinoblastoma cells</td>
<td>10.1.22</td>
<td>Klump</td>
<td></td>
</tr>
<tr>
<td>Farhoumand, Lina</td>
<td>Evaluation of the anti-tumor potential of beta-blockers in the tumor-spheroid-model of uveal-melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Petzold, Anne</td>
<td>Analyses of resistance and clonal evolution in ALK positive non-small cell lung cancers</td>
<td>24.1.22</td>
<td>Seifert</td>
<td></td>
</tr>
<tr>
<td>Montero Vergara, Jetsy</td>
<td>Characterisation of the molecular mechanism of autophagy inhibition by HER2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* BIOME Travel Award Talk